AmpliChip® CYP450 Test


The world's first microarray-based pharmacogenomic test cleared for clinical use.
The AmpliChip CYP450 Test provides comprehensive detection of gene variations — including deletions and duplications — for the CYP2D6 and CYP2C19 genes, which play a major role in the metabolism of an estimated 25% of all prescription drugs. It is intended to be an aid to clinicians in determining therapeutic strategy and treatment dose for therapeutics metabolized by the CYP2D6 or CYP2C19 gene product.
For a full listing of Roche Molecular Diagnostics Products, see